Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib
Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib
Recruiting · NCT05280509 · Registry updated 2023-02-21Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib | Hemic and Lymphatic Diseases, Myeloproliferative Disorders, bone marrow disorder, hematologic disorder, primary myelofibrosis | Recruiting | Phase 1 / Phase 2 | 2023-02-21 | NCT05280509 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Telios Pharma, Inc. | 3 |
19 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.